The History of Raloxifene: From Failed Contraceptive to Bone Drug
Raloxifene is a selective estrogen receptor modulator (SERM) best known today for treating and preventing osteoporosis in postmenopausal women and for reducing breast-cancer risk in certain high-risk patients. Its path to the clinic was anything but straight. Our editorial team traces how a compound that nearly died in development became a well-established medicine.
The SERM idea
By the 1960s and 1970s, researchers understood that estrogen drives the growth of many breast cancers. The search was on for compounds that could block estrogen in breast tissue. Tamoxifen, the first successful SERM, emerged from this effort and transformed breast-cancer treatment.
The deeper insight behind SERMs is that the estrogen receptor behaves differently in different tissues. A single molecule can act as an estrogen blocker in the breast while behaving like estrogen in bone. This tissue selectivity is what makes the class so interesting and so hard to design.
Raloxifene, originally known by the code keoxifene, was synthesized at Eli Lilly as part of this wave of SERM research. Chemically it belongs to the benzothiophene family, distinct from tamoxifen's triphenylethylene structure.
The early hope was simple: build a better anti-estrogen for breast cancer. Reality, as often happens in drug development, took the molecule somewhere its inventors did not expect.
Early development and a near-death
In the 1980s, keoxifene was tested as a potential breast-cancer treatment. The results were disappointing. In advanced breast cancer, it did not clearly outperform tamoxifen, and for a time the program lost momentum and was effectively shelved.
This is a common fate for experimental drugs. Many promising molecules stall when their first intended use does not pan out, and most are abandoned entirely. Keoxifene could easily have become one of those forgotten compounds.
What saved it was a shift in scientific thinking. Researchers, notably the work associated with V. Craig Jordan and colleagues, recognized that the drug's estrogen-like effects on bone and cholesterol might be valuable rather than a nuisance.
In other words, the property that made it a mediocre pure anti-estrogen, its mixed agonist-antagonist behavior, hinted at a completely different use. The question became not how to block estrogen everywhere, but how to harness its selectivity.
The pivot to bone health
After menopause, falling estrogen accelerates bone loss, raising the risk of osteoporosis and fractures. Estrogen replacement protects bone but carries risks to the breast and uterus. A drug that acted like estrogen in bone but not in those tissues would be valuable.
Raloxifene fit that description. In laboratory and then human studies, it preserved bone density while behaving as an anti-estrogen in breast tissue and, importantly, not stimulating the uterine lining the way tamoxifen can.
This repositioning turned a failed cancer drug into a candidate osteoporosis medicine. The clinical program refocused on postmenopausal bone loss, with fracture prevention as the key endpoint.
The strategy illustrates a broader lesson in pharmacology: a molecule's value is defined by matching its real biology to the right medical need, not by the use originally imagined for it.
| Era | Intended use | Outcome |
|---|---|---|
| 1980s | Advanced breast cancer | Underwhelming; program stalled |
| Early 1990s | Repositioned for bone | Protected bone density in studies |
| 1997 | Osteoporosis prevention | FDA approval |
| 1999 | Osteoporosis treatment | Indication expanded |
| 2007 | Breast-cancer risk reduction | Added indication |
Approval and the breast-cancer story
The FDA approved raloxifene in 1997 for preventing osteoporosis in postmenopausal women, and later for treatment. The pivotal evidence came largely from the MORE trial, which showed reduced vertebral fracture risk.
The MORE study produced an unexpected bonus. Women taking raloxifene for their bones had a markedly lower incidence of invasive estrogen-receptor-positive breast cancer. This reconnected the drug to its original purpose from a new direction.
That observation led to the large STAR trial, which compared raloxifene with tamoxifen for breast-cancer risk reduction in high-risk postmenopausal women. Raloxifene was comparable in reducing invasive breast cancer, with a somewhat different side-effect profile, including fewer uterine cancers and blood clots than tamoxifen.
On the strength of these data, the FDA approved raloxifene in 2007 for reducing breast-cancer risk in certain postmenopausal women, giving the molecule a second, formally recognized role.
Where raloxifene stands today
Raloxifene remains a useful but not first-line option. For osteoporosis, bisphosphonates and newer agents often take precedence, but raloxifene suits specific patients, particularly those also concerned about breast-cancer risk.
Its main safety concerns mirror estrogen's. It increases the risk of venous thromboembolism and, like estrogen, can worsen hot flashes and leg cramps. It carries an FDA boxed warning about blood clots and stroke risk in women with coronary heart disease.
In the world of sports pharmacology, SERMs are sometimes discussed for off-label purposes, but raloxifene's evidence base and approvals are firmly in postmenopausal women's health. It is not an approved performance or recovery agent.
The story's enduring value is scientific: it is a textbook example of drug repurposing and of how understanding receptor biology can rescue a molecule from the discard pile.
Conclusions of the editorial team
Raloxifene began as a breast-cancer hopeful, faltered, and was reborn as an osteoporosis drug once researchers appreciated its tissue-selective biology. Years later, it circled back to breast-cancer prevention.
Its history shows how the same molecule can fail and succeed depending on which of its effects you value and which patients you treat.
For patients, raloxifene is a reminder that drug selection is about matching a specific profile to a specific need under medical guidance.
Readers interested in related topics may enjoy our articles on how SERMs differ from aromatase inhibitors, on bone health after menopause, and on the history of tamoxifen.
References
- Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from the MORE randomized trial. JAMA. 1999;282(7):637–645.
- Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP STAR P-2 trial. JAMA. 2006;295(23):2727–2741.
- Jordan VC. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell. 2004;5(3):207–213.
- Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337(23):1641–1647.
- Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women. J Natl Cancer Inst. 2004;96(23):1751–1761.
